RGRX — RegeneRx Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $1.33m
- $0.08m
Brief: Regenerx Receives Stockholder Approval For Reverse Stock Split
Brief: First Patient Enrolled Into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial With Rgn-259
Brief: RegeneRx Publishes RGN-259 Phase 3 Clinical Trial Results
Brief: Regenerx Reports Topline Results Of Arise-3 Dry Eye Trial
Brief: RegeneRx Joint Venture Enrolls Last Subject In Phase 3 Dry Eye Trial
Brief: Regenerx Joint Venture Expects To Complete Phase 3 Dry Eye Trial In November 2020
Brief: RegeneRx Issues Advisory On Dry Eye Trial Amid COVID-19 Virus
Brief: Regenerx Announces New Board Member
Brief: RegeneRx Biopharmaceuticals announces $1.75 mln private placement
Brief: Regenerx, Lee's Pharm announce acceleration of RGN-259 development in China